• Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Lincoln Share Price

    Lincoln Pharmaceuticals Share PriceLincoln Pharmaceuticals

    Small Cap 4.1k Result
    ₹677.85
    5.2 (0.77%)
    As on 01 December, 2023 | 22:28 BSE: 531633 NSE: LINCOLNISIN: INE405C01035

    Lincoln Pharmaceuticals Performance

    Day Range

    • Low 671.00
    • High 689.00
    ₹ 677.85

    52 Week Range

    • Low 300.00
    • High 692.00
    ₹ 677.85
    • Open Price685.00
    • Previous Close672.65
    • Volume100662

    Start SIP in Lincoln Pharmaceuticals

    Start SIP

    Lincoln Pharmaceuticals Share Price

    • Over 1 Month 37.01%
    • Over 3 Month 32.92%
    • Over 6 Month 77.77%
    • Over 1 Year 98.87%

    Lincoln Pharmaceuticals Key Statistics

    P/E Ratio 16.8
    PEG Ratio
    Market Cap Cr 1,358
    Price to Book Ratio 2.7
    EPS 36.2
    Dividend 0.2
    Relative Strength Index 73.95
    Money Flow Index 83.77
    MACD Signal 33.43
    Average True Range 26.05

    Lincoln Pharmaceuticals Investment Rating

    • Master Rating:

    • Lincoln Pharmaceuticals has an operating revenue of Rs. 537.83 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 20% is great, ROE of 14% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 23% and 53% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 23% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 82 which is a GOOD score indicating consistency in earnings, a RS Rating of 85 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 75 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has great fundamentals and technical strength to stay in momentum.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Lincoln Pharmaceuticals Financials
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 156136112134141123103
    Operating Expenses Qtr Cr 1251159610711210785
    Operating Profit Qtr Cr 31211727291717
    Depreciation Qtr Cr 3322222
    Interest Qtr Cr 0010001
    Tax Qtr Cr 9649866
    Net Profit Qtr Cr 28191322241511
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 533482
    Operating Expenses Annual Cr 421377
    Operating Profit Annual in Cr 8995
    Depreciation Cr 98
    Interest Annual Cr 21
    Tax Annual Cr 2827
    Net Profit Annual Cr 7369
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 76
    Cash from Investing Activity Annual Cr -78
    Cash from Financing Annual Activity Cr -3
    Net Cash Flow Annual Cr -4
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 502433
    Fixed Assets Annual Cr 157148
    Total Non Current Assets Annual Cr 220182
    Total Current Assets Annual Cr 367353
    Total Assets Annual Cr 587534
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 251216
    ROE Annual % 1516
    ROCE Annual % 2022
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2222
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 156136112134141123103
    Operating Expenses Qtr Cr 1251159610711210785
    Operating Profit Qtr Cr 31211727291717
    Depreciation Qtr Cr 3322222
    Interest Qtr Cr 0010001
    Tax Qtr Cr 9649866
    Net Profit Qtr Cr 28191322241511
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 533482
    Operating Expenses Annual Cr 421377
    Operating Profit Annual in Cr 8995
    Depreciation Cr 98
    Interest Annual Cr 21
    Tax Annual Cr 2827
    Net Profit Annual Cr 7369
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 3976
    Cash from Investing Activity Annual Cr -37-78
    Cash from Financing Annual Activity Cr -5-3
    Net Cash Flow Annual Cr -2-5
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 502433
    Fixed Assets Annual Cr 157148
    Total Non Current Assets Annual Cr 220182
    Total Current Assets Annual Cr 367353
    Total Assets Annual Cr 587534
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 251216
    ROE Annual % 1516
    ROCE Annual % 2022
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2222
    Invest in Lincoln Pharmaceuticals

    Lincoln Pharmaceuticals Technicals

    EMA & SMA

    Current Price
    ₹677.85
    5.2 (0.77%)
    pointer
    • Bullish Moving Average
    • ___
    • 16
    • Bearish Moving Average
    • ___
    • 0
    • 20 Day
    • ₹615.75
    • 50 Day
    • ₹563.81
    • 100 Day
    • ₹517.02
    • 200 Day
    • ₹461.96
    • 20 Day
    • ₹612.07
    • 50 Day
    • ₹547.07
    • 100 Day
    • ₹504.46
    • 200 Day
    • ₹440.04

    Lincoln Pharmaceuticals Resistance and Support

    PIVOT
    ₹679.29
    Resistance
    First Resistance 687.57
    Second Resistance 697.28
    Third Resistance 705.57
    RSI 73.95
    MFI 83.77
    MACD Single Line 33.43
    MACD 37.82
    Support
    First Resistance 669.57
    Second Resistance 661.28
    Third Resistance 651.57

    Lincoln Pharmaceuticals Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 106,560 5,179,882 48.61
    Week 146,606 6,098,799 41.6
    1 Month 355,293 8,733,090 24.58
    6 Month 166,910 6,859,989 41.1

    Lincoln Pharmaceuticals Result Highlights

    Lincoln Pharmaceuticals Synopsis

    NSE-Medical-Diversified

    Lincoln Pharmace is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 510.31 Cr. and Equity Capital is Rs. 20.03 Cr. for the Year ended 31/03/2023. Lincoln Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 20/01/1995 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1995PLC024288 and registration number is 024288.
    Market Cap 1,358
    Sales 538
    Shares in Float 0.98
    No of funds 12
    Yield 0.23
    Book Value 2.71
    U/D Vol ratio 4
    LTDebt / Equity
    Alpha 0.25
    Beta 0.9

    Lincoln Pharmaceuticals

    Owner NameSep-23Jun-23Mar-23Dec-22
    Promoters 50.53%48.67%47%46.34%
    Mutual Funds
    Foreign Portfolio Investors 2.59%1.74%1.27%1.44%
    Individual Investors 37.47%37.32%37.04%36.61%
    Others 9.41%12.27%14.69%15.61%

    Lincoln Pharmaceuticals Management

    Name Designation
    Mr. Kishor M Shah Chairman
    Mr. Mahendra G Patel Managing Director
    Mr. Hashmukh I Patel Whole Time Director
    Mr. Munjal M Patel Whole Time Director
    Mr. Ashish R Patel Whole Time Director
    Mr. Rajnikant G Patel Director
    Mr. Ishwarlal A Patel Independent Director
    Mr. Pirabhai R Suthar Independent Director
    Mr. Meha M Patel Independent Director
    Mr. Saurin J Parikh Independent Director

    Lincoln Pharmaceuticals Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Lincoln Pharmaceuticals Corporate Action

    Date Purpose Remarks
    2023-11-02 Quarterly Results
    2023-08-10 Quarterly Results
    2023-05-25 Audited Results & Dividend
    2023-02-09 Quarterly Results
    2022-11-10 Quarterly Results

    Lincoln Pharmaceuticals MF Shareholding

    Name Amount(cr)
    Motilal Oswal S&P BSE Healthcare ETF 8

    Lincoln Pharmaceuticals FAQs

    What is Share Price of Lincoln Pharmaceuticals ?

    Lincoln Pharmaceuticals share price is ₹677 As on 01 December, 2023 | 22:14

    What is the Market Cap of Lincoln Pharmaceuticals ?

    The Market Cap of Lincoln Pharmaceuticals is ₹1357.7 Cr As on 01 December, 2023 | 22:14

    What is the P/E ratio of Lincoln Pharmaceuticals ?

    The P/E ratio of Lincoln Pharmaceuticals is 16.8 As on 01 December, 2023 | 22:14

    What is the PB ratio of Lincoln Pharmaceuticals ?

    The PB ratio of Lincoln Pharmaceuticals is 2.7 As on 01 December, 2023 | 22:14

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.